Aerocrine Enters Into a License Agreement With Medisoft

SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AERO-B) today announced the signing of a license agreement with Medisoft S.A. The agreement includes the withdrawal of all patent proceedings between the companies. Medisoft has entered into a license agreement with Aerocrine under Aerocrine’s European Patents EP 0 606 351, EP 0724 723, EP 1439 781, EP 1661 514, EP 1 545 305, EP 0 973 444 and EP 0 892 926 and their respective Indian and Australian counterparts. The royalty bearing license grants Medisoft the right to manufacture its current HypAir FeNO, HypAir FeNO+ and HypAir NO Nasal products in Belgium and to sell the products in Europe, Australia and India under Aerocrine’s patents.

Back to news